IDEAS home Printed from https://ideas.repec.org/a/oup/medlaw/v32y2024i1p20-41..html
   My bibliography  Save this article

Post-trial access to investigational drugs in India: addressing challenges in the regulatory framework

Author

Listed:
  • Nidhi Mehrotra
  • Padmavati Manchikanti

Abstract

Through the New Drugs and Clinical Trials Rules, 2019 (2019 Rules), India has developed the rules governing post-trial access (PTA) to new drugs or investigational new drugs. However, inconsistencies and interpretational challenges exist in the application of the 2019 Rules and the Indian Council of Medical Research Guidelines 2017. This conflation poses a real harm to the trial participants, specifically the ones with limited access to healthcare facilities. Since drug laws in India do not expressly deal with other forms of access like the ‘Compassionate Use’ or ‘Expanded Access’ mechanism, demarcating the scope and describing the strategies for PTA are the need of the hour. We propose possible strategies to address inadequacies in the regulatory regime and establish ‘win–win’ situations among all stakeholders. We further argue that India is well positioned to provide leadership by developing detailed PTA provisions and may set a potential path for the other clinical trial host countries.

Suggested Citation

  • Nidhi Mehrotra & Padmavati Manchikanti, 2024. "Post-trial access to investigational drugs in India: addressing challenges in the regulatory framework," Medical Law Review, Oxford University Press, vol. 32(1), pages 20-41.
    • Handle: RePEc:oup:medlaw:v:32:y:2024:i:1:p:20-41.
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1093/medlaw/fwad028
    Download Restriction: Access to full text is restricted to subscribers.
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:oup:medlaw:v:32:y:2024:i:1:p:20-41.. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Oxford University Press (email available below). General contact details of provider: https://academic.oup.com/medlaw .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.